Loading stock data…
ONC
$293.86-1.41 (-0.48%)
Pre-Market$294.49+0.63 (+0.21%)· Last close May 1
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BeOne Medicines AG in the Healthcare sector is trading at $293.86. The stock is currently 24% below its 52-week high of $385.22, remaining 8.3% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why ONC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$293.86
Potential Downside
86.4%
Whystock Fair Value$39.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus26 analysts
Mean target$408.20+38.9%
Range$333.00 – $498.00
Fundamentals
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$34.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
126.48
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.07%
Volume
Today's trading volume
116,037
Recent News
BeOne Medicines price target lowered to $411 from $412 at Truist
Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm expect
BeOne Medicines (ONC) Is Up 9.4% After FDA Orphan Status And New Analyst Coverage For Liver Cancer
In recent days, BeOne Medicines AG gained fresh attention as Wolfe Research initiated coverage with an Outperform rating and the company secured FDA orphan drug designation for its hepatocellular carcinoma candidate, adding to a portfolio anchored by oncology brands such as Brukinsa and Tevimbra. This combination of external validation from a new analyst and regulatory support for a liver cancer therapy reinforces the breadth and perceived quality of BeOne’s oncology pipeline. We’ll now...
Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating
BeOne Medicines AG (NASDAQ:ONC) is one of the 7 Fastest Growing European Stocks to Invest In. On March 26, 2026, Wolfe Research analyst Kalpit Patel initiated coverage on BeOne Medicines AG (NASDAQ:ONC) with an Outperform rating and a $340 price target, saying the company runs one of the broadest development programs in biotech. The analyst […]
BeOne Medicines (ONC) Downgraded Despite Strong Oncology Portfolio
BeOne Medicines AG (NASDAQ:ONC) ranks among the oversold European stocks to buy. On March 16, Jefferies lowered BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy and reduced its price target to $290 from $420. According to analyst Faisal Khurshid, Brukinsa continues to be one of the strongest assets in hematology and is predicted to continue […]
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion
BeOne Medicines Ltd (ONC) reports robust revenue growth and outlines plans to solidify its leadership in oncology and immunology.